ClinicalTrials.gg
Status unknownNCT03282253Updated Nov 27, 2017

Elevated Stearoyl-CoA Desaturase-1 Expression Predicts the Disease Severity of Severe Acute Pancreatitis

An observational study in Acute Pancreatitis and Organ Failure, Multiple, sponsored by Nanjing University School of Medicine. Status unknown. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-11-27.

Sponsored by Nanjing University School of Medicine · Observational

The sponsor has not verified this record recently (last verified Nov 2017), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
216
Ages
18 Years to 75 Years
Sex
All
01

Study summary

In this study, the investgatiors aimed to investigate the associations between serum levels of stearoyl-CoA desaturase-1(SCD-1) and the disease severity as well as the presence of adverse clinical events, such as local complications, organ failure, mortality and so on.In this prospective study, participants were divided into two groups based on serum SCD-1 concentration on admission and prospectively observe the disease severity and clinical outcomes of them.

02

Conditions studied

  • Acute Pancreatitis
  • Organ Failure, Multiple
03

In context

Pancreatitis

557 studies on the registry are indexed under Pancreatitis; 164 are open to participants now.

This study's planned enrollment of 216 is close to the median of 200 across 192 observational studies indexed under Pancreatitis.

Browse Pancreatitis studies →

Lead sponsor

Nanjing University School of Medicine is the lead sponsor of 39 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

patients with the diagnosis of acute pancreatitis (Atlanta standard), abdominal pain occurred within one week of admission; we intended to include the severer cases (APACHEII score is more than 8 and Ranson score is greater than 3).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of acute pancreatitis (Atlanta standard), abdominal pain occurred within one week of admission;
  2. APACHEII score is more than 8 and Ranson score is greater than 3;
  3. Age 18-75;
  4. Obtaining .

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy pancreatitis;
  2. Patients with the following disease history: severe cardiac, pulmonary, renal, liver function insufficiency or immunodeficiency disease.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
216 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. the incidence rate of infected pancreatic necrosis

    Time frame: 2-4 week after disease onset

Secondary outcomes

  1. the incidence rate of organ failure

    the incidence rate of organ failure (transient or persistent)

    Time frame: 1-2 week after disease onset

  2. the incidence rate of local complications

    acute peripancreatic fluid collections, pancreatic pseudocycts, acute necrotic collections and walled-off necrosis

    Time frame: 1-2 week after disease onset

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03282253
Lead sponsor
Nanjing University School of Medicine
Responsible party
Weiqin Li (Director of Department of Surgical Intensive Care Unit, Nanjing University School of Medicine) — Principal investigator
First posted
Sep 13, 2017
Start date
Jan 1, 2018 (estimated)
Primary completion
Dec 30, 2018 (estimated)
Completion
Jun 30, 2019 (estimated)
Last update
Nov 27, 2017

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion